Comparative Pharmacology
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus KENALOG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus KENALOG.
FLUDROCORTISONE ACETATE vs KENALOG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
Triamcinolone acetonide is a synthetic corticosteroid with potent glucocorticoid and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production and immune cell migration.
0.1 mg orally once daily, range 0.05-0.2 mg/day
Kenalog (triamcinolone acetonide) 40-80 mg intramuscularly (deep gluteal) every 4 weeks; or 0.5-1 mg/kg intravenously every 24 hours (for acute conditions).
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Terminal half-life ~2-5 hours (triamcinolone acetonide); clinical duration prolonged due to crystalline depot formulation
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Renal (primarily as metabolites), ~30% unchanged; biliary/fecal minor (≤10%)
Category D/X
Category C
Corticosteroid
Corticosteroid